Sort
23,748 grants matching “melanoma”
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$671,059Elad Ziv · University Of California, San Francisco · R01 · FY2021 · CA
Multidisciplinary Collaborative Clinical Research, Core Facilities and Other Clinical Services in NIDDK Program Area Diseases
$671,045James Balow · National Institute Of Diabetes And Digestive And Kidney Diseases · ZID · FY2014 · DK
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
$670,933Gerald S Shadel · Salk Institute For Biological Studies · R01 · FY2018 · CA
Identification of Covalent Transcriptional Dependencies in Melanoma
$670,836Liron Bar-Peled · Massachusetts General Hospital · R01 · FY2025 · CA
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
$670,756Timothy A Marlowe · Faknostics, Llc · R42 · FY2022 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$670,711James R. Heath · Institute For Systems Biology · U01 · FY2021 · CA
Skin Disease Research Center
$670,662Brigham And Women'S Hospital · P30 · FY2004 · AR
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$670,576James R. Heath · Institute For Systems Biology · U01 · FY2020 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$670,441Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2024 · CA
T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade
$670,428Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2021 · CA
Project 3: Integrative approach tounderstanding the mechanism ofcostimulation
$670,406Arlene H Sharpe · Yale University · P01 · FY2019 · AI
Dissecting Phenotype Switching in Early Stage Melanomas
$670,266Julide T Celebi · New York University School Of Medicine · R01 · FY2022 · CA
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
$670,182Anna Karolina Palucka · Jackson Laboratory · R01 · FY2020 · CA
Inflammation-mediated Insulin Resistance and Oncogenesis
$670,006Michel Bernier · Aging · Z01 · FY2007 · AG
Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
$669,970Beth A. Reboussin · Wake Forest University Health Sciences · U01 · FY2023 · CA
Resistance mechanisms to autophagy-modulating therapies
$669,910Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2022 · CA
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
$669,855Garret A Fitzgerald · University Of Pennsylvania · R01 · FY2021 · HL
Imaging Acidosis and Immune Therapy in PDAC
$669,832Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Imaging Acidosis and Immune Therapy in PDAC
$669,832Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Project 3: Integrative approach tounderstanding the mechanism ofcostimulation
$669,787Arlene H Sharpe · Yale University · P01 · FY2020 · AI
NCI National Clinical Trials Network-Network Lead Academic Participating Site
$669,699Lawrence E Flaherty · Wayne State University · U10 · FY2014 · CA
Ms. LILAC: Muscle Mass in the Life and Longevity After Cancer (LILAC) Study
$669,634Hailey Rose Banack · State University Of New York At Buffalo · R37 · FY2023 · CA
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling
$669,574Mark A. Lemmon · Yale University · R01 · FY2023 · CA
Regulation of Ras-Dependent Signal Transduction Pathways
$669,409Deborah Morrison · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
THE FRAMINGHAM SCHOOL STUDY OF NEVI IN CHILDREN SONIC II
$669,406Allan C Halpern · Sloan-Kettering Inst Can Research · R01 · FY2013 · AR